For hepatic specification, the study identified a novel small-molecule cocktail, VDF (Vitamin C, Dihexa, and Forskolin), that could effectively substitute for expensive growth factors like BMPs, FGFs, and HGF
Homogenates were able to remove 35% of the GST-GFP from the protein solution (Figure 2B) while microspheres bind a similar amount of GST-GFP (Figure 6) at 10 fold less mass
Researchers investigate Big picture view: In the study, researchers at the University of Virginia specifically investigated small-molecule GLP-1 receptor agonists, such as the Food and Drug Administration (FDA)-approved orforglipron, which can be taken orally and are cheaper to produce than their injectable counterparts
Repeat as needed and follow with maintenance treatments
Adverse event reporting and FDA inspection readiness require ongoing investment in quality systems and documentation